Stem Cell Therapeutic and Research Reauthorization Act of 2025
Bill Summary
Reauthorizes funding for stem cell research and therapy programs. Extends existing programs to continue studying and developing stem cell treatments.
Sponsored By
Bill Journey
- Sep 4, 2025
- May 21, 2026You Are Here
The committee will review the bill, debate amendments, and vote on whether to advance it to the full chamber.
- TBD
The full chamber debates the bill, may amend it, and votes on whether to pass it.
- TBD
If passed by the first chamber, the other chamber considers, may amend, and votes on the bill.
- TBD
If passed by both chambers, the bill goes to the President to sign into law or veto.
Why It Matters
This bill affects patients with diseases or injuries that could be treated with stem cell therapies, as well as researchers and scientists working on stem cell projects, by providing continued funding for their work. It also impacts the biomedical industry by supporting the development of new stem cell-based treatments.
Impact Areas
Support & Opposition
- Democratic9
- Republican9
Documents
1
Full text opens on congress.gov, the official source.
Cosponsors (21)
- Doris O. MatsuiDemocrat · CA
- Gus M. BilirakisRepublican · FL
- Chellie PingreeDemocrat · ME
- Claudia TenneyRepublican · NY
Show all 13 moreShow less
- Kweisi MfumeDemocrat · MD
- Michelle FischbachRepublican · MN
- Debbie DingellDemocrat · MI
- Josh GottheimerDemocrat · NJ
- Robert B. AderholtRepublican · AL
- Nicole MalliotakisRepublican · NY
- Kathy CastorDemocrat · FL
- Andrew R. GarbarinoRepublican · NY
- Eleanor Holmes NortonDemocrat · DC
- Cliff BentzRepublican · OR
- Nanette Diaz BarragánDemocrat · CA
- Brad FinstadRepublican · MN
- Kelly MorrisonDemocrat · MN
4 more not shown here — see the full list on congress.gov.
Bill Details
- Health
Summary and impact analysis written by Judy (KnowGov's enrichment AI). Bill metadata, status, sponsor, and any floor votes from Prism. Sections marked “Sample” are placeholders not yet connected to live data.

















